Sanofi Cash Flow from Financial Activities 2010-2025 | SNY
Sanofi annual/quarterly cash flow from financial activities history and growth rate from 2010 to 2025. Cash flow from financial activities can be defined as the net amount of cash transactions used in funding activities
- Sanofi cash flow from financial activities for the quarter ending March 31, 2025 was $-0.624B, a 0% increase year-over-year.
- Sanofi cash flow from financial activities for the twelve months ending March 31, 2025 was $-6.764B, a 53.03% decline year-over-year.
- Sanofi annual cash flow from financial activities for 2024 was $-6.236B, a 28.44% decline from 2023.
- Sanofi annual cash flow from financial activities for 2023 was $-8.715B, a 42.09% increase from 2022.
- Sanofi annual cash flow from financial activities for 2022 was $-6.133B, a 26.53% decline from 2021.
Sanofi Annual Cash Flow Financial
(Millions of US $) |
| 2024 |
$-6,236 |
| 2023 |
$-8,715 |
| 2022 |
$-6,133 |
| 2021 |
$-8,348 |
| 2020 |
$-7,408 |
| 2019 |
$-4,696 |
| 2018 |
$4,646 |
| 2017 |
$-8,932 |
| 2016 |
$-4,538 |
| 2015 |
$-3,973 |
| 2014 |
$-6,886 |
| 2013 |
$-4,949 |
| 2012 |
$-5,596 |
| 2011 |
$4,029 |
| 2010 |
$-6,171 |
| 2009 |
$-1,098 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharma |
$136.671B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
